Last reviewed · How we verify
Inactivated SARS-CoV-2 vaccine
This inactivated vaccine trains the immune system to recognize and neutralize SARS-CoV-2 by presenting killed viral particles that cannot cause infection.
This inactivated vaccine trains the immune system to recognize and neutralize SARS-CoV-2 by presenting killed viral particles that cannot cause infection. Used for Prevention of COVID-19 in adults and adolescents.
At a glance
| Generic name | Inactivated SARS-CoV-2 vaccine |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | Inactivated viral vaccine |
| Target | SARS-CoV-2 spike protein and other viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains chemically or physically inactivated SARS-CoV-2 virions that stimulate both humoral (antibody) and cellular (T-cell) immune responses without risk of productive infection. Upon exposure to the antigen, B cells produce neutralizing antibodies against viral surface proteins, particularly the spike protein, while T cells develop memory to mount rapid responses upon future viral encounter.
Approved indications
- Prevention of COVID-19 in adults and adolescents
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
- Nausea
Key clinical trials
- An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older (PHASE2)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- COVID-19 Booster and IIV Schedule in Immunocompromised Hosts (PHASE2)
- Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study (PHASE4)
- Vaccine Responses in Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: